Please assess the completion status of the following clinical trial:

Trial Title: Postmenopausal Women and Their Endothelium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Early post-menopausal women who are within 1-6 years following their final menstrual cycle~* Late post-menopausal women who are beyond 6 years following their final menstrual cycle~Exclusion Criteria:~* Individuals with any overt cardiovascular, metabolic, hematologic, pulmonary, renal, musculoskeletal, and/or neurological disease(s).~* Users of any tobacco and/or nicotine products (smokers, chewing tobacco, nicotine-containing patches/gum, smokeless cigarettes)~* Individuals with a BMI \> 35~* Individuals with resting blood pressure \> or = 130/80 mm Hg~* Individuals with high blood lipids (total cholesterol \> or = 240 mg/dl, LDL \> or = 160 mg/dl, triglycerides \> or = 200 mg/dl).~* Postmenopausal women with hyperglycemia (fasting glucose \> or = 110 mg/dl and HbA1c \>6.0%).~* Individuals taking any of the following medications:~  1. blood pressure lowering medication (e.g., beta blockers, ACE inhibitors, angiotensin antagonists, calcium channel blockers, diuretics)~ 2. lipid- lowering medication (e.g., statins)~ 3. nitrates (e.g. nitroglycerin) for angina~ 4. phosphodiesterase inhibitors (e.g., Viagra)~ 5. anti-Inflammatory drugs~* Individuals taking hormone therapy

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nitrate rich beetroot juice (Type: ACTIVE_COMPARATOR): Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
- Nitrate depleted beetroot juice (Type: PLACEBO_COMPARATOR): Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).